The Latest Breaking News from Albert Bourla

The drugmaker has shed nearly $180 billion in market cap after struggling to chart a new course as the COVID-19 pandemic waned.

Pfizer's CEO Albert Bourla is trying to reposition the global pharmaceutical giant for a post-pandemic world

A Belgian court on Friday heard a lawsuit accusing European Commission chief Ursula von der Leyen of secretly negotiating Covid vaccine purchases via text message and arguing she should be barred from a second term.

While the S&P 500 Index's dividend yield is just about half of its long-term averages, Ford and Pfizer are two dividend-paying stocks that offer healthy yields. Plus, their cheap valuations mean that there is a reasonable probability of upside over the next couple of years.

Pfizer issued a disappointing 2024 forecast Wednesday, denting shares as the company navigates a profound plunge in sales tied to the Covid-19 pandemic.

Pfizer announced Tuesday that it expects to complete this week its $43 billion acquisition of cancer-focused biotech company Seagen after clearing key regulatory hurdles.

The fallout from the Israel-Hamas war has spilled into workplaces everywhere, with corporate leaders from the highest ranks of prominent companies weighing in with their views while workers complain their voices are not being heard

Bourla hopes to bring the same speed in developing a COVID vaccine to discovering new cancer treatments.

"What we are doing now, I don’t think anyone has done so far," Pfizer CEO Albert Bourla says.

Pfizer (PFE) continues to make significant strides in the pharmaceutical industry, given its recent acquisition and drug approvals. Is the stock a buy, sell, or hold now? Keep reading to find out….

Pfizer’s Albert Bourla is among the CEOs who signed a letter against suspending mifepristone, citing its impact on the FDA and the biotech industry.